Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05866172 | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | unknown | Phase 3 | 264 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04967495 | TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT | unknown | N/A | 171 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05859945 | Navigating the Clinical Trial Process for Hepatocellular Carcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT04111029 | Liquid Biopsy in Hepatocellular Carcinoma(HCCGenePanel) | unknown | — | 30 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05837065 | Prognostic Models for HCC Based on Tumor Micronecrosis | unknown | — | 765 | Zhejiang UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05822453 | Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04652440 | Ablation Combined With PD-1 in HCC: Phase II Study | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05816837 | Displacement Distance and Stabilization Time for Liver Fiducial Marker | unknown | — | 30 | Peking University Third HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04906174 | Effect of Materials for Subcuticular Suture (Quill vs. Monocryl) on Complications After Liver Resection | unknown | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | unknown | Early Phase 1 | 30 | Sohag UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809869 | Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | unknown | Phase 2 | 25 | The University of Hong KongOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05806333 | [18F]FAPI PET/CT in Suspicious Focal Liver Lesions Without FDG Avidity | unknown | N/A | 60 | Jilin UniversityOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03990623 | CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization | unknown | N/A | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05800561 | Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on Cirrhosis(ProHype-ICG) | unknown | — | 208 | Federico II UniversityOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05653180 | IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 20 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT04601961 | Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients | unknown | N/A | 220 | The University of Hong KongOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT04010071 | Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04211168 | Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers | unknown | Phase 2 | 44 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04368078 | Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 76 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05048017 | Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05670561 | Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma | unknown | Phase 4 | 60 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05723705 | Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)(LIVEROBOT) | unknown | — | 3,600 | Amsterdam UMC, location VUmcOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05781074 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）(CASTLE-08) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05781581 | A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection | unknown | — | 50,000 | RenJi HospitalOTHER | 0 | Mar 23, 2023 | clinicaltrials |
| NCT04663035 | Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC | unknown | Phase 2 | 120 | Ming ZhaoOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05407519 | A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection | unknown | Phase 2 | 40 | Anhui Provincial HospitalOTHER_GOV | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05616390 | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05764551 | The Application of Serum DNA Methylation for Patients With HCC | unknown | N/A | 100 | Chiayi Christian HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05633342 | Project CADENCE (CAncer Detected Early caN be CurEd)(CADENCE) | unknown | — | 15,000 | MiRXES Pte LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03803436 | Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation(COLT) | unknown | Phase 2 | 22 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05770635 | Polyvinyl Alcohol Embolization Microspheres | unknown | N/A | 224 | Shanghai Huihe Medical Technology Co., LtdINDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05759858 | Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma | unknown | — | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760430 | The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05760599 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | unknown | Phase 2 | 30 | Shi MingOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05192460 | Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer | unknown | N/A | 30 | jianming xuOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05374122 | AI Guidance for Biopsy in Suspected Cholangiocarcinoma | unknown | N/A | 48 | Instituto Ecuatoriano de Enfermedades DigestivasOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05675462 | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 25 | Fudan UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05694845 | Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 6, 2023 | clinicaltrials |
| NCT05706974 | Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 19, 2023source: clinicaltrials